+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07830199

Open-Label Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SHR-4595 Injection in Adults with Advanced Solid Tumors

Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-11-02

208

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating SHR-4595 injection in adults with advanced solid tumors to assess its safety, tolerability, and pharmacokinetics. This Phase I clinical study aims to identify the dose-limiting toxicity, maximum tolerated dose, and the recommended dose for future Phase II studies. Participants eligible for this study have measurable disease and an Eastern Cancer Cooperative Group ECOG performance status of 0 or 1, with life expectancy of at least 12 weeks. Participants receive SHR-4595 injection at different doses, with the study focusing on determining the best dosing levels. The treatment period monitors adverse events from the first day of dosing through 40 days after the last dose, with ongoing evaluation of dose-limiting toxicity, maximum tolerated dose, and recommended Phase II dose tracked up to 12 months. The study is open-label and conducted at multiple centers. During the study, participants undergo regular assessments to monitor safety and treatment effects, including evaluations of progression-free survival, objective response rate, disease control rate, duration of response, and overall survival over a 12-month period. Adverse events and other safety data are closely followed to understand the treatments tolerability. The total participation duration can extend up to one year from the first dose.

CONDITIONS

Brief Title

A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics

Research Team

H

Hongxia Han

Y

Yuanchao Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here